Pmgc Holdings Clinical Trial Data
PMGC Holdings announced results from a preclinical study of its engineered probiotic candidate EL-32, both as a standalone and in combination with semaglutide. The study identified a statistically significant greater absolute lean mass at the highest EL-32 dose compared to semaglutide alone, supporting the company's muscle-preservation thesis. While the combination improved insulin sensitivity and reduced body weight, it did not demonstrate a consistent additive metabolic benefit over semaglutide alone across all measures.